VectraCor, Inc. has developed and patented a technology that will differentiate the current mature cardiac monitoring and ECG market by enhancing the cardiac monitor to actually derive a 12-22 lead ECG from the conventional placement of 5 electrodes, instead of using a separate ECG machine that will require an additional 10 electrodes.  The Technology will allow the calculation of a 12, 16, 19, or 22 lead (n-lead ECG) from the measurement of only 3 standard ECG leads or 5 electrodes.

Additionally, and perhaps more importantly, VectraCor’s technology will also incorporate the world's first electrical cardiac marker, VectraplexAMI, that in real-time will detect ECG changes that may be indicative of a patient developing an acute myocardial infarction (AMI- heart attack). The VectraplexAMI will be displayed on the cardiac monitor/ECG machine in the same manner as the heart rate.  The current gold standard for detecting an AMI is to (1) place patient on a cardiac rhythm monitor (requiring the placement of 3-5 electrodes on the patient chest wall), (2) measure the standard 12-lead ECG (requiring the placement of an additional 10 electrodes on the limbs and chest wall), and (3) measure the trend of cardiac “serum” blood markers obtained for lab analysis every 4-6 hours during an 18-24 hour period of acute care observation. 

 

VectraCor’s technology will perform all three processes mentioned above with only 5 electrodes and, as a result of our unique algorithms and technology,  can detect an AMI in seconds.  This advancement will dramatically improve patient care while potentially reducing time and costs. VectraCor’s technology will continue to monitor the patient, beat-to-beat (with the same 5 electrode placement) and derive the patient’s 12-lead ECG (and up to 22 leads) directly from the cardiac rhythm monitor.  This dramatically improves current technology and diagnostic capability, while potentially reducing the overall healthcare costs for cardiovascular disease (CVD) which is the #1 cause of death in the US and the world.

News:

July 2010 - VectraCor receives support from Verizon Wireless for the development of the Vectraplex Holter System. VectraCor will utilize the Verizon Wireless service to send real time pateint data for immediate review and diagnosis by a physician.  Verizon Wireless believes it will be a market/industry leading device.

VectraCor is granted additional patent protection  in Japan - August 2010

VectraCor is granted addtional patent protection in China - July 2010

Awards:

VectraCor is Awarded the " Judges Choice Award" at the NJTC Venture Conference on March 26, 2010.  The New Jersey Technology Council provides business support, networking opportunities, information, advocacy and recognition of technology companies and their leaders.

VectraCor is awarded grant from The Commission on Science and Technology of the State of New Jersey.  The Edison Innovation R&D Fund  will provide grants on a competitive basis.  In November 2009, The Edison Innovation R&D Fund notified VectraCor and 7 other companies of their award.  The grant ranges from $100,000 to $500,000, which VectraCor is pleased to receive a $500,000 grant.  The grant is to develop an ambulatory holter monitoring system that incorporates VectraCor's proprietary IP.

Events and Meetngs:

American College of Emergency Physicians - September 28, 2010
Dr. Schreck's paper, "Eigenvalue Analysis as an Electrical Cardiac Biomarker to Identify Acute Myocardial Infarction", incorporated in Vectracor's products is accepted and being presented on Tuesday, September 28 at 10:45 a.m.
Las Vegas, Nevada

NJTC Venture Conference
The Palace at somerset Park, NJ
March 26, 2010

American Heart Association
Orlando, Florida
November 14-17th, 2009
Booth #2012

Heart Rhythm Society 2009 Convention
Boston, MA
May 13-16th, 2009

American College of Emergency Physicians accepts Abstract
The Derived Electrocardiogram and a Cardiac Electrical Marker for Acute Myocardial Infarct
October 28, 2008 - McCormick Place - Chicago

Products are not available in the US for Sale